Lineage Cell Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $1,408 | $1,444 | $2,088 | $1,246 |
Gross Profit | 1,222 | 1,171 | 1,657 | 1,077 |
EBITDA | -5,725 | -6,486 | -6,187 | -6,469 |
EBIT | -5,867 | -6,661 | -6,362 | -6,645 |
Net Income | -5,760 | -6,542 | -4,775 | -7,110 |
Net Change In Cash | 1,408 | 1,444 | 2,088 | 1,246 |
Free Cash Flow | -5,226 | -5,821 | -6,110 | -5,176 |
Cash | 29,622 | 43,576 | 35,442 | 31,474 |
Basic Shares | 188,813 | 182,909 | 172,663 | 174,868 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $8,945 | $14,703 | $3,896 | $773 |
Gross Profit | 7,582 | 13,975 | 2,470 | 388 |
EBITDA | -24,041 | -19,824 | -52,791 | -25,012 |
EBIT | -24,733 | -20,551 | -53,678 | -27,123 |
Net Income | -21,486 | -26,353 | -38,564 | -20,685 |
Net Change In Cash | 8,945 | 14,703 | 3,896 | 773 |
Cost of Revenue | -43,468 | 23,114 | 23,150 | |
Free Cash Flow | -29,240 | 646 | -23,915 | -19,817 |
Cash | 35,442 | 11,355 | 55,742 | 32,585 |
Basic Shares | 172,663 | 169,792 | 164,502 | 150,044 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.03 |
2024-03-31 | -$0.04 |
2023-12-31 | -$0.03 |
2023-09-30 | -$0.04 |
